Protein corona hampers targeting potential of MUC1 aptamer functionalized SN-38 core-shell nanoparticles

International Journal of Pharmaceutics

Volumn 494, Issue 1, 2015, Pages 430-444

  Varnamkhasti, Behrang Shiri ^a   Hosseinzadeh, Hosniyeh ^a   Azhdarzadeh, Morteza ^a   Vafaei, Seyed Yaser ^a   Esfandyari Manesh, Mehdi ^a   Mirzaie, Zahra H ^a   Amini, Mohsen ^a   Ostad, Seyed Nasser ^a   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hyaluronic acid; MUC1 aptamer; Nanoparticle; Protein corona; SN 38

Indexed keywords

CHITOSAN NANOPARTICLE; CORONA PROTEIN; FIRTECAN; MUCIN 1; PROTEIN; UNCLASSIFIED DRUG; APTAMER; CAMPTOTHECIN; CHITOSAN; DRUG CARRIER; HYALURONIC ACID; IRINOTECAN; MUC-X PROTEIN, HUMAN; NANOPARTICLE; PROTEIN CORONA;

AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL VIABILITY; COLON CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CONJUGATION; DRUG RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTERNALIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HAMSTER; METABOLISM; PARTICLE SIZE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; APTAMERS, NUCLEOTIDE; CALORIMETRY, DIFFERENTIAL SCANNING; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; CHITOSAN; CRICETINAE; DRUG CARRIERS; DRUG LIBERATION; HUMANS; HYALURONIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; MUCIN-1; NANOPARTICLES; PARTICLE SIZE; PROTEIN CORONA;

EID: 84940549117     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.08.060     Document Type: Article

References (43)

1. B.K. Alldredge, M.A. Koda-Kimble, L.Y. Young, W.A. Kradjan, and B.J. Guglielmo Applied Therapeutics: the Clinical Use of Drugs 2013 Wolters Kluwer/Lipincot William & Wilkins
2. A.S. Barbas, and R.R. White The development and testing of aptamers for cancer Curr. Opin. Invest. Drugs (London, England: 2000) 10 2009 572 578
3. J.D. Byrne, T. Betancourt, and L. Brannon-Peppas Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Deliv. Rev. 60 2008 1615 1626
4. P. Calvo, C. Remunan-Lopez, J. Vila-Jato, and M. Alonso Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers J. Appl. Polym. Sci. 63 1997 125 132
5. J. Cheng, K.T. Khin, G.S. Jensen, A. Liu, and M.E. Davis Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates Bioconjugate Chem. 14 2003 1007 1017
6. J.-K. Cho, C. Chun, H.-J. Kuh, and S.-C. Song Injectable poly(organophosphazene)-camptothecin conjugate hydrogels: synthesis, characterization, and antitumor activities Eur. J. Pharm. Biopharm. 81 2012 582 590
7. M.K. Cowman, and S. Matsuoka Experimental approaches to hyaluronan structure Carbohydr. Res. 340 2005 791 809
8. S. Dhar, F.X. Gu, R. Langer, O.C. Farokhzad, and S.J. Lippard Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. 105 2008 17356 17361
9. P. Ebrahimnejad, R. Dinarvand, A. Sajadi, M.R. Jafari, F. Movaghari, and F. Atyabi Development and validation of an ion-pair HPLC chromatography for simultaneous determination of lactone and carboxylate forms of SN-38 in nanoparticles J. Food Drug Anal. 17 2009 246 256
10. P. Ebrahimnejad, R. Dinarvand, A. Sajadi, M.R. Jaafari, A.R. Nomani, E. Azizi, M. Rad-Malekshahi, and F. Atyabi Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines Nanomed. Nanotechnol. Biol. Med. 6 2010 478 485
11. O.C. Farokhzad, J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, J.P. Richie, and R. Langer Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc. Natl. Acad. Sci. 103 2006 6315 6320
12. O.C. Farokhzad, J.M. Karp, and R. Langer Nanoparticle-aptamer bioconjugates for cancer targeting Expert Opin Drug Deliv. 3 2006 311 324
13. C.S. Ferreira, M.C. Cheung, S. Missailidis, S. Bisland, and J. Gariépy Phototoxic aptamers selectively enter and kill epithelial cancer cells Nucleic Acids Res. 37 2009 866 876
14. F. Gu, R. Langer, and O.C. Farokhzad Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery Micro and Nano Technologies in Bioanalysis 2009 Springer 589 598
15. F.A. Haggar, and R.P. Boushey Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors Clin. Colon Rectal Surg. 22 2009 191 197
16. J.K. Herr, J.E. Smith, C.D. Medley, D. Shangguan, and W. Tan Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells Anal. Chem. 78 2006 2918 2924
17. A. Jain, and S.K. Jain In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors Eur. J. Pharm. Sci. 35 2008 404 416
18. S. Jaracz, J. Chen, L.V. Kuznetsova, and I. Ojima Recent advances in tumor-targeting anticancer drug conjugates Bioorg. Med. Chem. 13 2005 5043 5054
19. C. Kang Gene therapy - developments and future perspectives M. Bujak, I. Ratkaj, M.B. Loncar, R. Spaventi, S.K. Pavelic, Small Interfering RNAs: Heralding a New Era in Gene Therapy 2011 Intech pp 71 92
20. Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51 1991 4187 4191
21. M. Khati The future of aptamers in medicine J. Clin. Pathol. 63 2010 480 487
22. J.Y. Lee, and A.P. Spicer Hyaluronan: a multifunctional, megaDalton, stealth molecule Curr. Opin. Cell Biol. 12 2000 581 586
23. E. Levy-Nissenbaum, A.F. Radovic-Moreno, A.Z. Wang, R. Langer, and O.C. Farokhzad Nanotechnology and aptamers: applications in drug delivery Trends Biotechnol. 26 2008 442 449
24. M. Mahmoudi, I. Lynch, M.R. Ejtehadi, M.P. Monopoli, F.B. Bombelli, and S. Laurent Protein-nanoparticle interactions: opportunities and challenges Chem. Rev. 111 2011 5610 5637
25. M. Mahmoudi, A.M. Abdelmonem, S. Behzadi, J.H. Clement, S. Dutz, M.R. Ejtehadi, R. Hartmann, K. Kantner, U. Linne, and P. Maffre Temperature: the ignored factor at the nanobio interface ACS Nano 7 2013 6555 6562
26. F. Marcucci, and F. Lefoulon Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress Drug Discov. Today 9 2004 219 228
27. V. Mirshafiee, M. Mahmoudi, K. Lou, J. Cheng, and M.L. Kraft Protein corona significantly reduces active targeting yield Chem. Commun. 49 2013 2557 2559
28. K. Mladenovska, O. Cruaud, P. Richomme, E. Belamie, R. Raicki, M.-C. Venier-Julienne, E. Popovski, J.-P. Benoit, and K. Goracinova 5-ASA loaded chitosan-Ca-alginate microparticles: preparation and physicochemical characterization Int. J. Pharm. 345 2007 59 69
29. M.P. Monopoli, C. Åberg, A. Salvati, and K.A. Dawson Biomolecular coronas provide the biological identity of nanosized materials Nat. Nanotechnol. 7 2012 779 786
30. A. Nasti, N.M. Zaki, P. de Leonardis, S. Ungphaiboon, P. Sansongsak, M.G. Rimoli, and N. Tirelli Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation Pharm. Res. 26 2009 1918 1930
31. M. Ramesh, P. Ahlawat, and N.R. Srinivas Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives Biomed. Chromatogr. 24 2010 104 123
32. E. Sayari, M. Dinarvand, M. Amini, M. Azhdarzadeh, E. Mollarazi, Z. Ghasemi, and F. Atyabi MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery Int. J. Pharm. 473 2014 304 315
33. N. Sepehri, H. Rouhani, A.R. Ghanbarpour, M. Gharghabi, F. Tavassolian, M. Amini, S.N. Ostad, M.H. Ghahremani, and R. Dinarvand Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment BioMed Res. Int. 2014 2014 1
34. A. Serafino, M. Zonfrillo, F. Andreola, R. Psaila, L. Mercuri, N. Moroni, D. Renier, M. Campisi, C. Secchieri, and P. Pierimarchi CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis Curr. Cancer Drug Targets 11 2011 572 585
35. J. Sudimack, and R.J. Lee Targeted drug delivery via the folate receptor Adv. Drug Deliv. Rev. 41 2000 147 162
36. N. Vijayalakshmi, A. Ray, A. Malugin, and H. Ghandehari Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation Bioconjugate Chem. 21 2010 1804 1810
37. D. Walczyk, F.B. Bombelli, M.P. Monopoli, I. Lynch, and K.A. Dawson What the cell sees in bionanoscience J. Am. Chem. Soc. 132 2010 5761 5768
38. M. Wang, and M. Thanou Targeting nanoparticles to cancer Pharmacol. Res. 62 2010 90 99
39. V.J. Wielenga, K.-H. Heider, G. Johan, A. Offerhaus, G.R. Adolf, F.M. van den Berg, H. Ponta, P. Herrlich, and S.T. Pals Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression Cancer Res. 53 1993 4754 4756
40. C.C. Williams, S.H. Thang, T. Hantke, U. Vogel, P.H. Seeberger, J. Tsanaktsidis, and B. Lepenies RAFT-derived polymer-drug conjugates: poly(hydroxypropyl methacrylamide)(hpma)-7-ethyl-10-hydroxycamptothecin (SN-38) conjugates ChemMedChem 7 2012 281 291
41. H. Zhang, J. Wang, W. Mao, J. Huang, X. Wu, Y. Shen, and M. Sui Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: In vitro and in vivo studies J. Controlled Release 166 2013 147 158
42. H. Zhao, C. Lee, P. Sai, Y.H. Choe, M. Boro, A. Pendri, S. Guan, and R.B. Greenwald 20-O-acylcamptothecin derivatives: evidence for lactone stabilization J. Org. Chem. 65 2000 4601 4606
43. H. Zhao, B. Rubio, P. Sapra, D. Wu, P. Reddy, P. Sai, A. Martinez, Y. Gao, Y. Lozanguiez, and C. Longley Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers Bioconjugate Chem. 19 2008 849 859